[Effects of core proteoglycan on the transdifferentiation of human renal tubular epithelial cell induced by transforming growth factor-beta1 in vitro].
OBJECTIVE
To study the effects of core proteoglycan on the transdifferentiation of human renal tubular epithelial cell induced by transforming growth factor beta1 (TGF-beta1) in vitro.


METHODS
The cultured HK-2 cells were divided into six groups: A. negative control group; B. 10 ng/ml TGF-beta1 group; C. 10 ng/ml core proteoglycan treated group; D. 100 ng/ml core proteoglycan treated group; E. 10 ng/ml TGF-beta1 + 10 ng/ml core proteoglycan group; F. 10 ng/ml TGF-beta1 + 100 ng/ml core proteoglycan group. The changes in configuration of HK-2 cells were inspected 48 hours after adding the stimulating factor. At the same time, changes in mRNA of keratin, alpha-smooth muscle actin, vimentin were analyzed.


RESULTS
Compared with group A, group B showed great changes in the morphology of cells, most cells converted into spindle shape, like fibroblast; groups E and F, especially group F showed significantly reduced spindle shape cells. Compared with group A, groups C and D had no significant changes in morphology of cells Compared with 10 ng/ml TGF-beta1 group and negative control, the mRNA expression of alpha-smooth muscle actin and vimentin had significant increase, but that of keratin reduced (P < 0.05). However, after combined treatment with TGF-beta1 and core proteoglycan, alpha-smooth muscle actin and vimentin expression were reduced significantly, while expression of keratin was up-regulated. Single core proteoglycan treated group and negative control group had no dramatic differences (P > 0.05).


CONCLUSIONS
TGF-beta1 can induce the transdifferentiation of human renal tubular epithelial cell and core proteoglycan has some inhibitory effect on transdifferentiation of human renal tubular epithelial cell induced by TGF-beta1 in vitro.
Cheng
Xue-qin
XQ
Nanjing Children Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China.
Bao
Hua-ying
HY
Chen
Ying
Y
Pan
Xiao-qin
XQ
Fei
Li
L
Chen
Rong-hua
RH
D000199:Actins / Q000502:physiology; D055419:Bone Morphogenetic Protein 7 / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D002460:Cell Line; D048430:Cell Shape; D054338:Cell Transdifferentiation; D002478:Cells, Cultured; D055513:Connective Tissue Growth Factor / Q000494:pharmacology*; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D005347:Fibroblasts / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D007684:Kidney Tubules / Q000473:pathology*; D007687:Kidney Tubules, Proximal / Q000473:pathology*; D011509:Proteoglycans / Q000737:chemistry / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000494:pharmacology; D053773:Transforming Growth Factor beta1 / Q000737:chemistry / Q000494:pharmacology*; D014746:Vimentin / Q000378:metabolism
D000199:Actins; D055419:Bone Morphogenetic Protein 7; D015820:Cadherins; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D014746:Vimentin; D055513:Connective Tissue Growth Factor